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Abstract
Overcoming resistance to chemotherapy is a major challenge in
colorectal cancer (CRC) treatment, especially since the underlying
molecular mechanisms remain unclear. We show that silencing of
the prolyl hydroxylase domain protein PHD1, but not PHD2 or
PHD3, prevents p53 activation upon chemotherapy in different CRC
cell lines, thereby inhibiting DNA repair and favoring cell death.
Mechanistically, PHD1 activity reinforces p53 binding to p38a
kinase in a hydroxylation-dependent manner. Following p53–p38a
interaction and chemotherapeutic damage, p53 can be phosphory-
lated at serine 15 and thus activated. Active p53 allows nucleotide
excision repair by interacting with the DNA helicase XPB, thereby
protecting from chemotherapy-induced apoptosis. In accord with
this observation, PHD1 knockdown greatly sensitizes CRC to 5-FU
in mice. We propose that PHD1 is part of the resistance machinery
in CRC, supporting rational drug design of PHD1-specific inhibitors
and their use in combination with chemotherapy.
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Introduction
Resistance to chemotherapy remains a major clinical issue in the
treatment of colorectal cancer (CRC). Response rates have already
improved to about 30–40% over the past years with the introduction
of the currently used FOLFOX and FOLFIRI regimens in patients
with metastatic CRC, however still leaving room for further research
on potential candidates causing chemorefractory disease (Prenen
et al, 2013).
Prolyl hydroxylase domain proteins PHD1, PHD2, and PHD3
(codified by EGLN2, EGLN1, and EGLN3, respectively) are oxygen-
sensitive enzymes initially known for their ability to target the
hypoxia-inducible transcriptional factors HIF-1a and HIF-2a for
proteasomal degradation (Epstein et al, 2001). Besides controlling
cellular adaptation to hypoxic conditions, it is now clear that PHDs
are also involved during cell damage and metabolic stress (Aragones
et al, 2008; Schneider et al, 2010; Leite de Oliveira et al, 2012).
Recently, we have shown that inhibition of PHD2 mounts an adap-
tive response in mice treated with chemotherapeutic drugs, resulting
in the protection against their toxic side effects (Leite de Oliveira
et al, 2012). Additionally, PHD1 or PHD2 inhibition confers organ
protection against ischemic damage (Aragones et al, 2008; Schnei-
der et al, 2010; Takeda et al, 2011). However, proteins other than
HIF-1a and HIF-2a (including PKM2, FOXO3a, ATF4, RPB1, HCLK2,
and b2-adrenergic receptor) have been proven to be alternative
targets of PHD1–3 (Epstein et al, 2001; Mikhaylova et al, 2008; Chan
et al, 2009; Xie et al, 2009, 2012; Xue et al, 2010; Ameln et al, 2011;
Hiwatashi et al, 2011; Takeda et al, 2011; Scholz et al, 2013; Wong
et al, 2013; Zheng et al, 2014). In some cases, substrate hydroxyla-
tion by PHD1–3 does not initiate a consensus for proteasomal
degradation. For example, RPB1 is positively regulated by PHD1-
mediated hydroxylation (Mikhaylova et al, 2008). This suggests that
many PHD targets and functions are still undiscovered. This is also
reflected by the lack of a conclusive role for PHDs in the context of
cancer biology in general. More specifically in CRC, PHD2 and
PHD3 have been suggested to act as tumor suppressors because of
their decreased expression in the cancer compared to the normal
tissue (Chan et al, 2009; Xue et al, 2010). However, the expression
data on PHD1 in CRC are not unison with some studies reporting
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decreased expression of PHD1 and others showing no alterations
(Jubb et al, 2009; Rawluszko et al, 2013). Importantly, none of
these studies correlate the activity (rather than the expression) of
these enzymes to disease onset and outcome or even, more specifi-
cally, to CRC response to chemotherapeutic regimens.
The transcription factor p53 is undoubtedly the most character-
ized cell stress sensor and tumor suppressor. p53 is usually phos-
phorylated and activated upon oncogene activation and DNA
damage resulting in growth arrest and DNA repair or cell death
induction, depending on the extent of the damage (Vousden & Lane,
2007). In CRC, p53 is mutated in about 50% of patients. However,
p53 is never the primary hit and a clear correlation between p53
mutations and patient survival has never been proven (Tejpar et al,
2010), suggesting that p53 could potentially play both a sensitizing
and desensitizing role against chemotherapy, depending on the
cellular context as previously proposed (Ferreira et al, 1999). By
using in vitro and in vivo mouse models, in this study, we investi-
gate whether and how PHDs and p53 are intertwined and play a role
in the resistance toward chemotherapy in colorectal cancer.
Results
PHD1 silencing hinders p53 activation upon
chemotherapy treatment
To evaluate the possible effect of PHD1–3 on p53 activation upon
chemotherapy treatment, we silenced EGLN2, EGLN1, or EGLN3
(coding for PHD1, PHD2, and PHD3, respectively) in p53wt/wt
HCT116 cells (also denoted HCT116) (Sur et al, 2009) and treated
them with 5-FU. PHD1, PHD2, and PHD3 RNA transcripts after
knockdown were reduced, respectively, by 86.4, 91.1 and 84.7%
compared to the scrambled control (Fig 1B). Evaluation of p53 acti-
vation was done by Western blotting for p53 phosphorylation at
Ser15 (p53 pS15), frequently associated with the initial steps of p53
activation (Meek & Anderson, 2009). Indeed, upon 5-FU treatment,
HCT116 showed an increased p53 accumulation and phosphorylation
at Ser15 in the scrambled control cells (Fig 1A). Silencing of PHD2 or
PHD3 did not affect either p53 levels or phosphorylation both at
baseline and after 5-FU treatment. However, PHD1 knockdown
significantly reduced p53 phosphorylation at Ser15 upon 5-FU
treatment comparing to the scrambled control (Fig 1A and C). Similar
results were obtained by using a different siRNA against PHD1
(Fig 1D and E).
To address whether the reduction in p53 phosphorylation upon
PHD1 silencing also holds true upon different chemotherapeutics
clinically used in CRC treatment, we exposed HCT116 to either
SN-38 or oxaliplatin. In scrambled control cells, both drugs induced
p53 phosphorylation, which was largely prevented upon silencing
of PHD1 (Fig 1F). To extend our findings to different CRC cell lines
other than HCT116, we used LIM1215 carrying wild-type p53 (Chen
et al, 2014). PHD1 mRNA levels were 82.1% reduced in PHD1-
silenced cells comparing to their scrambled control (Fig 1G). Treat-
ment with 5-FU resulted in increased p53 levels and increased p53
phosphorylation at Ser15 compared to untreated cells; PHD1 silenc-
ing strongly prevented this induction (Fig 1H).
Altogether, these data provide evidence that, in the context of
colorectal cancer, a drop in PHD1 levels reduces p53 phosphorylation
following the administration of three different chemotherapeutics
commonly used in the clinical treatment of CRC.
PHD1 silencing sensitizes colorectal cancer
cells to chemotherapy
In order to find out whether the reduction in p53 phosphorylation
after chemotherapy following PHD1 knockdown could affect cell
death in a p53-dependent manner, we treated PHD1-silenced p53wt/wt
HCT116 and the previously described p53/ HCT116 lacking
full-length p53 (Sur et al, 2009) with 5-FU for 24 h (Fig EV1A). As
expected, the treatment caused the cleavage of caspase-3 and parp in
p53wt/wt HCT116; however, this induction was further enhanced
upon silencing of PHD1 (Fig 2A). Though caspase-3 cleavage was
also induced in p53/ HCT116 cells (albeit to a lower extent), it was
not enhanced upon silencing of PHD1, suggesting that PHD1 might
underlie resistance to chemotherapy by modulating p53 phosphoryla-
tion (Fig 2A). The same results were confirmed by FACS analysis on
HCT116 cells stained with propidium iodide, by ELISA nucleosome
detection and by TUNEL immunofluorescence staining of fixed cells
(Figs 2B and EV1B and C). These findings were recapitulated by using
a second siRNA against PHD1 (Fig 2C). Similar to what was observed
with 5-FU, treatments with either SN-38 or oxaliplatin were also able
to promote apoptosis of p53wt/wt HCT116 cells and this response was
further enhanced by PHD1 silencing (Fig 2D and E). To validate our
observations in a different cell type, we showed that PHD1 silencing
was also able to sensitize p53wt/wt LIM1215 cells to 5-FU (Fig 2F).
To link the effect of PHD1 silencing on chemoresponse to the
negative regulation of p53 phosphorylation at Ser15, we made use
of p53/ HCT116 cells and reconstituted them with either wild-type
Figure 1. Silencing of PHD1 decreases p53 phosphorylation in response to chemotherapy in CRC cells.
A Western blot for p53, phosphorylated p53 at Ser15 (p53 pS15), and vinculin (vinc) in HCT116 treated with 300 lM 5-FU for 8 h and silenced for PHD1, PHD2, or PHD3.
B qRT–PCR for PHD1, PHD2, and PHD3 in HCT116 silenced for PHD1 (*P = 0.0006 toward Scr), PHD2 (*P = 0.0004 toward Scr), or PHD3 (*P = 0.0075 toward Scr).
A two-tailed unpaired t-test was performed with n = 3/group.
C Western blot of p53 pS15, p53, PHD1, and vinculin in HCT116 treated with 300 lM 5-FU for 8 h and silenced for PHD1 or a scrambled (Scr) control.
D qRT–PCR for PHD1 showing silencing efficacy with both siRNAs 1 (*P = 0.0017 toward Scr) and 2 (*P = 0.0023 toward Scr) compared to the scrambled control in
HCT116. A two-tailed unpaired t-test was performed with n = 3/group.
E Western blot for p53, p53 pS15, and vinc in HCT116 silenced for PHD1 with two different constructs (constructs 1 and 2) upon exposure to 300 lM 5-FU for 8 h.
F Western blot for p53 pS15, p53, and vinculin in HCT116 silenced for PHD1 and treated with either 200 nM SN-38 or 20 lM oxaliplatin for 8 h.
G RNA levels of PHD1 in LIM1215 silenced for PHD1. (*P = 0.0099 toward Scr in a two-tailed unpaired t-test with n = 3/group.)
H Western blot for p53 pS15, p53, and vinc in LIM1215 upon silencing of PHD1 and treatment for 8 h with 200 lM 5-FU.
Data information: Vinculin (vinc) was used as a loading control in (A, C, E, F, H).
Source data are available online for this figure.
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Figure 1.
EMBO Molecular Medicine Vol 7 | No 10 | 2015 ª 2015 The Authors
EMBO Molecular Medicine PHD1 causes CRC resistance to chemotherapy Sofie Deschoemaeker et al
1352
p53 (p53wt?p53/ HCT116) or p53 mutated at Ser15 (p53S15A?
p53/ HCT116). When measuring cell death, p53wt?p53/
HCT116 responded to 5-FU similar to their p53wt/wt HCT116 coun-
terpart, and correspondingly, PHD1 silencing resulted in an increase
in parp cleavage upon 5-FU treatment compared to control cells
(Fig EV1D). In contrast, p53S15A?p53/ HCT116 no longer showed
a differential apoptotic response in scrambled control and PHD1-
silenced cells (Fig 2G). Consistently, PHD1 silencing in p53wt?
p53/ HCT116 cells reduced p53 Ser15 phosphorylation in
response to 5-FU treatment, while p53 phosphorylation at Ser15 was
not detected in p53S15A?p53/ HCT116 cells, confirming the
specificity of the signal (Fig EV1E). Altogether, these data show that
PHD1 inhibition can chemosensitize colorectal cancer cells by
hindering p53 phosphorylation at Ser15.
PHD1 silencing improves the response of CRC to 5-FU treatment
To evaluate whether the aforementioned findings are also relevant
in more complex systems, we initially performed a colony formation
assay in p53wt/wt HCT116 carrying a doxycycline-inducible shScr or
shPHD1 construct. After treatment for 24 h with 1 lg/ml of doxycy-
cline, cells were exposed to 5-FU in combination with doxycycline
and then assessed for the ability to form foci in vitro. In the scram-
bled control, 5-FU treatment decreased colony formation compared
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Figure 2. Silencing of PHD1 increases cell apoptosis after chemotherapy.
A Western blot for p53, cleaved caspase-3 (cleaved casp3), cleaved parp, and vinculin (vinc) in p53wt/wt and p53/ HCT116 silenced for PHD1 upon exposure to
300 lM 5-FU for 24 h, showing an increased apoptotic response to 5-FU treatment in PHD1-silenced cells compared to the scrambled control.
B Confirmation of these results by FACS analysis of propidium iodide-stained PHD1-silenced p53wt/wt and p53/ HCT116 cells exposed for 26 h to 300-lM 5-FU treatment.
*P = 0.002 toward p53wt/wt HCT116 shScr 5-FU-treated (two-tailed unpaired t-test) with n = 6 for non-treated p53wt/wt HCT116 and n = 3 in all other groups.
C Detection of cleaved casp3, cleaved parp, and vinc in HCT116 silenced with a second siRNA for PHD1.
D, E Apoptosis as detected byWestern blot for cleaved casp3 and parp in PHD1-silenced HCT116 treated for 20 h with 200 nM SN-38 (D) or for 24 h with 20 lMoxaliplatin (E).
F Western blot for cleaved casp3, parp, and vinc in LIM1215 silenced for PHD1 and treated for 24 h with 200 lM 5-FU.
G Similar apoptosis levels were detected by Western blot for cleaved casp3 and parp with vinc as a loading control in p53S15A?p53/ HCT116 silenced for PHD1 or
scrambled (Scr) control and treated for 20 h with 300 lM 5-FU.
Data information: Vinc is used as a loading control in (A, C–G).
Source data are available online for this figure.
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to the untreated cells, but this difference was even further decreased
upon silencing of PHD1 (Figs 3A and EV2A). In contrast, no
differences in colony formation capacity were detected between
PHD1-silenced and control p53/ HCT116 cells upon their
treatment with 5-FU (Fig EV2A and B), highlighting the dependency
of p53 in the PHD1-mediated resistance against cytostatic drugs.
Following these results, we investigated the preclinical relevance
of these findings in vivo. To this end, nude mice were sub-
cutaneously injected with p53wt/wt or p53/ HCT116, where condi-
tional silencing of PHD1 was achieved by doxycycline administra-
tion when tumors reached 250 mm3. Forty-eight hours after
doxycycline administration, mice received a weekly treatment with
the maximum tolerated dose of 100 mg/kg 5-FU. While tumor
growth was not altered in untreated mice carrying p53wt/wt HCT116
shScr or shPHD1 tumors, 5-FU treatment reduced tumor volume by
39.5% in p53wt/wt HCT116 shScr, but by 70% in mice carrying a
tumor silenced for PHD1 (Fig 3B). In contrast, 5-FU-treated mice
carrying p53/ HCT116 shScr or shPHD1 tumors did not show any
differences in tumor growth, providing evidence for the p53 depen-
dency of these findings (Fig 3C). These results show that PHD1
silencing can increase the sensitivity of CRC to chemotherapeutic
drugs both in vitro and in vivo in a p53-dependent manner.
PHD1 hydroxylase promotes p53 phosphorylation
upon chemotherapy
Mechanistically, PHDs have been shown to affect other proteins in
both hydroxylation-dependent and hydroxylation-independent
manners (Mikhaylova et al, 2008; Chan et al, 2009; Xue et al, 2010;
Hiwatashi et al, 2011; Takeda et al, 2011; Zheng et al, 2014). To
evaluate whether the enzymatic function of PHD1 was required for
p53 regulation, scrambled and PHD1-silenced HCT116 cells were
treated with the non-specific prolyl hydroxylase inhibitor DMOG in
the presence or absence of 5-FU. DMOG treatment alone did not
significantly affect p53 levels or phosphorylation at Ser15; however,
it did decrease p53 phosphorylation upon 5-FU treatment in control
cells, thus mimicking the effect of PHD1 knockdown. PHD1 silenc-
ing did not further reduce the phosphorylation of p53 (Fig 4A),
providing evidence that PHD1 promotes p53 phosphorylation
through its hydroxylase function. To exclude that HIFs could play a
role in this process as they have been shown to influence p53 levels
and activity (Sermeus & Michiels, 2011), we silenced HIF-1a or
HIF-2a in combination with PHD1 in HCT116. Upon treatment with
5-FU, silencing of PHD1 in combination with HIF-1a or HIF-2a
knockdown still impaired p53 Ser15 phosphorylation compared to
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Figure 3. PHD1 silencing sensitizes CRC to 5-FU treatment in mice.
A Representative images and quantification of the colony formation capacity of p53wt/wt HCT116 cells transduced with a doxycycline-inducible shScr or shPHD1
silencing construct, treated for 24 h with doxycycline with or without additional treatment for 8 h with 300 lM 5-FU. *P = 0.008 toward shScr, two-tailed unpaired
t-test and n = 3/group.
B Tumor volume of p53wt/wt HCT116 cells transduced with a doxycycline-inducible shScr or shPHD1 silencing construct injected subcutaneously in nude mice and
treated with 5-FU. *P = 0.045 toward shScr 5-FU-treated mice by two-way ANOVA with n = 6 for p53wt/wt HCT116 shScr, n = 7 for p53wt/wt HCT116 shPHD1 and
p53wt/wt HCT116 shScr 5-FU-treated, and n = 8 for p53wt/wt HCT116 shPHD1 5-FU-treated.
C Tumor volume of p53/ HCT116 cells transduced with a doxycycline-inducible shScr or shPHD1 silencing construct injected subcutaneously in nude mice and treated
with 5-FU. n = 6 for p53/ HCT116 shScr, p53/ HCT116 shPHD1, and p53/ HCT116 shScr 5-FU-treated and n = 8 for p53/ HCT116 shPHD1 5-FU-treated.
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the scrambled control (Fig EV3A–C), indicating that PHD1-mediated
p53 regulation is HIF independent.
To investigate whether PHD1 could interact with p53, Flag-
tagged PHD1 was overexpressed in HEK293T cells and immunopre-
cipitated using anti-Flag antibodies. From this analysis, we observed
that endogenous p53 was able to bind PHD1 (Fig 4B). Furthermore,
to evaluate whether this interaction was direct or indirect, we
immunoprecipitated recombinant Flag-tagged PHD1 in the presence
of recombinant p53. Also in this experimental setting, PHD1 was
able to pull down p53, proving a direct interaction of these two
proteins (Fig 4C). We next wanted to see whether endogenous
PHD1 interacts with endogenous p53 in HCT116 cells. To this end,
we immunoprecipitated p53 from p53wt/wt HCT116 cells and probed
the precipitate with PHD1 and p53 antibodies. To control binding
specificity, we also used p53/ or PHD1-silenced HCT116 cells and
performed an IP with an unrelated IgG control antibody. The data
obtained show that PHD1 could interact with p53 also at the
endogenous level in HCT116 (Fig 4D).
In summary, we can conclude that PHD1 through its hydroxyla-
tion function and binding with p53 allows p53 phosphorylation at
Ser15 upon chemotherapy treatment.
Reduced p53 hydroxylation impairs p38a-mediated
p53 phosphorylation
To study how PHD1 silencing could affect p53 phosphorylation at
Ser15, we first assessed which of the known p53-kinases were
involved in p53 phosphorylation at Ser15. Therefore, we silenced
Chk1, Chk2, ATR, ATM, p38a, and DNA-PK in HCT116 cells upon
treatment with 5-FU (Bode & Dong, 2004; Meek & Anderson, 2009)
(Fig EV4A and B). Unexpectedly, at least under the experimental
conditions tested, only p38a silencing could completely reduce p53
phosphorylation at Ser15 to a similar extent as silencing of PHD1
(Fig EV4A). To confirm whether PHD1 could indeed affect p53
phosphorylation through p38a, we silenced PHD1 and p38a, alone
or in combination (Figs 5A and EV4C). After treatment with 5-FU,
silencing of both p38a and PHD1 did not show an additive reduction
in p53 phosphorylation at Ser15, therefore suggesting that PHD1
hydroxylase function allows proper p53 phosphorylation by p38a
(Fig 5A). To further confirm the specificity of these findings for
p38a, we performed an in vitro kinase assay with p38a, p38b, and
p38c on p53 isolated from cells expressing either a control
(mirSIMA) or an artificial miRNA against PHD1 (mirPHD1). This
revealed that only phosphorylation of p53 by p38a, but not by p38b
or p38c, was prevented when PHD1 was lacking (Fig 5B). Finally,
we proved that, upon 5-FU treatment, PHD1 silencing significantly
reduced p53 binding to p38, confirming that hydroxylation of p53 is
required for p38 interaction to p53 (Fig 5C). These data show that
lack of PHD1 prevents proper p53 phosphorylation through a
reduced binding of p53 to p38a upon chemotherapy treatment.
PHD1 silencing reduces p53-mediated DNA repair
following chemotherapy
To investigate how the silencing of PHD1 could result in an
increased apoptotic response, we initially focused our attention on
A
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Figure 4. PHD1 hydroxylase is required for p53 phosphorylation upon chemotherapy treatment.
A Western blot for p53 pS15, p53, and vinculin (vinc) in PHD1-silenced HCT116 upon treatment with 300 lM 5-FU for 8 h with or without 0.5 mM DMOG for 26 h.
Vinculin (vinc) is used as a loading control.
B Western blot detection of PHD1-Flag and p53 in whole cell extracts (WCE) or after immunoprecipitation against the Flag-tag of overexpressed PHD1-Flag in HEK293T
cells.
C Western blot detection of PHD1-Flag and p53 after immunoprecipitation against the Flag-tag of recombinant PHD1-Flag incubated with recombinant p53.
D Western blot for p53 and PHD1 in WCE or after immunoprecipitation of endogenous p53 in p53wt/wt HCT116 cells, silenced with a Scr control, siPHD1, or sip53, or
after immunoprecipitation of p53wt/wt HCT116 cell lysates with an IgG control.
Source data are available online for this figure.
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the transcription of several important target genes of p53 such as
CDKN1A, GADD45, MDM2, BAX, and PUMA (Menendez et al,
2009). Although all these genes were induced by 5-FU treatment in
the scrambled control condition, PHD1 silencing did not affect their
transcription compared to the control both at baseline and upon
5-FU treatment (Fig 6A). Therefore, we evaluated whether transcrip-
tional activity was at all required for this specific process by treating
HCT116 cells with 5-FU together with the transcription inhibitor
a-amanitin. The proper function of the compound was confirmed by
quantification of PUMA transcription, a downstream target of p53
(Fig EV5A). Silencing of PHD1 was still able to increase parp cleav-
age upon combined treatment with 5-FU and a-amanitin. Thus
suggesting that p53-mediated transcription is not the cause for the
increased cell death observed after chemotherapy upon PHD1 silen-
cing (Fig 6B). In line with this, we also evaluated apoptosis after
5-FU treatment in p53R248/ HCT116, carrying a p53 DNA contact
mutant, incapable of DNA binding and transcription despite a well-
preserved tridimensional structure (Muller & Vousden, 2013). As
already suggested by the use of a-amanitin, also in these cells we
noted that silencing of PHD1 upon 5-FU treatment could still reduce
Ser15 phosphorylation (Fig 6C and D) and results in increased apop-
tosis as detected by Western blot for cleaved caspase-3 (Fig 6E).
These experiments confirm the importance of a transcription-
independent function of p53.
As p53 has been shown to influence DNA repair in a transcrip-
tion-independent manner, and as DNA repair can increase the resis-
tance of cancer cells toward chemotherapy (Bouwman & Jonkers,
2012; Gordon & Nelson, 2012), we evaluated the DNA damage
present in the cells. Indeed upon 5-FU treatment, DNA damage,
detected by phosphorylation of histone H2AX (pH2AX) as a marker,
was induced in the scrambled control and this was further increased
in PHD1-silenced cells (Fig 7A). The increased DNA damage conse-
quent to PHD1 silencing after chemotherapy treatment was p53
dependent as pH2AX accumulation in p53/ HCT116 upon 5-FU
treatment was equal in either the presence or absence of PHD1
(Fig 7A). More specifically, the reduced phosphorylation of p53 at
Ser15 is required for the increased DNA damage, as there are no
longer differences between the Scr control and siPHD1 condition in
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Figure 5. PHD1 hydroxylase favors p38a-mediated p53 phosphorylation.
A Western blot for p53 pS15, p53, and vinculin (vinc) in HCT116 treated with 300 lM 5-FU upon silencing of PHD1 and p38a, alone or in combination. Vinculin (vinc) is
used as a loading control.
B Detection of p53 pS15 and p53 after in vitro phosphorylation by p38a, p38b, or p38c of p53 immunoprecipitated from cells silenced for a control (SIMA) or PHD1.
C Detection by Western blot of p53 and p38 from whole cell extracts (WCE) or after immunoprecipitation of p53 from cell silenced for a Scr control or siPHD1 and
treated for 1 h with 300 lM 5-FU.
Source data are available online for this figure.
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pH2AX accumulation upon 5-FU treatment in the p53S15A?p53/
HCT116 cells (Figs 7B and EV1D). These results were also
confirmed with a second siRNA against PHD1 (Fig 7C) as well as
upon SN-38 or oxaliplatin treatment (Fig 7D) and in the p53R248/
HCT116 cells (Fig 7E).
Previous studies have shown that p53 can stimulate the
nucleotide excision repair (NER) pathway (engaged after 5-FU-,
SN-38-, and oxaliplatin-induced DNA damage) in a transcription-
independent manner through its direct interaction with XPB and
XPD, two components of transcription factor II human (TFIIH)
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Figure 6. PHD1 silencing increases apoptosis in a transcription-independent manner.
A Transcription analysis of CDKN1A, GADD45, MDM2, BAX, PUMA in PHD1-silenced p53wt/wt HCT116 either untreated or treated for 8 h with 300 lM 5-FU.
B Western blot for cleaved parp and vinculin (vinc) in PHD1-silenced HCT116 treated for 20 h with 300 lM 5-FU alone or in combination with 3 lg/ml a-amanitin.
C PHD1 mRNA levels in p53R248/ HCT116 silenced for PHD1. *P = 0.0005 toward scrambled control with a two-tailed unpaired t-test and n = 3/group.
D Western blot for p53 pS15, p53, and vinculin in PHD1-silenced p53R248/ HCT116 upon 8-h treatment with 300 lM 5-FU.
E Western blot for cleaved casp3 and vinculin in p53R248/ HCT116 silenced for PHD1 and treated with 300 lM 5-FU for 24 h.
Data information: Vinc was used as a loading control in (B, D, E). Mean values  s.e.m.
Source data are available online for this figure.
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(Sengupta & Harris, 2005). When assessing the physical interac-
tion of p53 with XPB or XPD, we noticed that PHD1 knockdown
strongly reduced the binding of p53 and XPB upon treatment with
5-FU (Fig 7F), whereas no interaction between XPD and p53 was
detected (Fig EV5B). To confirm that indeed, these findings are
dependent on XPB, we silenced PHD1 either alone or in combina-
tion with XPB in HCT116 treated with 5-FU (Fig EV5C). The
silencing of XPB caused a strong induction of DNA damage as
detected by pH2AX upon 5-FU treatment and this was not further
enhanced upon additional silencing of PHD1 (Fig 7G). These data
show that impaired binding of p53 to XPB is indeed the underly-
ing cause of the reduced DNA repair capacity of the cells after
PHD1 blockade. In essence, the reduced p53 phosphorylation at
Ser15 upon PHD1 silencing reduces p53 binding to XPB in the
NER complex upon chemotherapeutic challenge, thereby increas-
ing DNA damage and consequently cell death upon cytostatic
insult (Fig 7H).
Discussion
Chemotherapy remains the most widely used cancer treatment. In
the past, much attention has been paid on the mechanisms underly-
ing chemotherapy resistance. In our study, we aimed to investigate
the interplay between PHDs and p53 and their potential role in the
response of CRC to chemotherapy. The model we propose relies on
PHD1 hydroxylase function allowing p38a-dependent phosphoryla-
tion of p53 in response to cytostatic damage in colorectal cancer cell
lines. As a consequence, p53 can interact with the NER machinery
and more specifically with XPB. This promotes DNA repair and
results in the resistance to chemotherapy (Fig 7H, left panel). On
the other hand, when PHD1 is inhibited, the p53-kinase p38a
can no longer bind, and therefore, p53 phosphorylation upon
chemotherapy treatment is prevented. It follows that p53 is not any
longer able to bind XPB, thereby impairing the DNA repair capacity
linked to p53 activity. This leads to increased DNA damage and cell
death in response to the chemotherapeutic treatment (Fig 7H, right
panel).
With these findings, we are adding another layer of complexity to
the role of PHD1 in cancer. Previous reports have shown that murine
PHD1, when overexpressed in colorectal cancer cells, can decrease
tumor growth through the reduction of HIF-1a and VEGF (Erez et al,
2003). On the other hand, a reduction in PHD1 levels in breast cancer
can hinder tumor growth due to the accumulation of FOXO3a and
consequent suppression of cyclin D1 eventually leading to a decreased
proliferation (Zhang et al, 2009; Zheng et al, 2014). In non-cancerous
cells, the situation is even more complex with increased HIF-2a and
MYC-dependent proliferation in liver tissue of Phd1 KO mice after
liver resection (Mollenhauer et al, 2012), but decreased proliferation
upon PHD1 silencing in HeLa ovarian cells because of reduced
hydroxylation of the centrosome component Cep192 (Moser et al,
2013) or eventually decreased enterocyte apoptosis in Phd1 knockout
mice affected by colitis (Tambuwala et al, 2010). In our current study,
we uncover that PHD1 silencing does not affect the colony formation
capacity and tumor growth under basal conditions, but it increases
sensitivity of CRC cells toward the cytostatic effects of chemothera-
peutic drugs such as 5-FU, SN-38, or oxaliplatin in vitro and in vivo.
These effects are independent of HIF signaling as proven by: (i) direct
interaction of PHD1 and p53, (ii) PHD1-mediated p53 regulation, (iii)
the absence of detectable HIF-2a levels, (iv) the lack of modulation of
HIF-1a by PHD1 silencing, and (v) reduced phosphorylation at Ser15
of p53 upon 5-FU treatment after silencing of PHD1 even in the
absence of HIF-1a or HIF-2a. Together with our experiments in
p53/ HCT116 cells supporting the p53 dependency of the effects on
DNA damage, apoptosis, and colony formation upon PHD1 regula-
tion, these findings exclude the possibility that the previously shown
interplay between HIFs and p53 (Sermeus & Michiels, 2011) can take
part in the mechanism here described.
With our work, we show that PHD1 binds to p53 and that its
hydroxylase function is required for the effects observed on p53
phosphorylation. This would suggest that indeed, p53 could be
hydroxylated. The direct binding of p53 to PHD1 observed
in vitro supports this hypothesis, as no other intermediate
proteins are required for the interaction. Hereby, prolyl hydroxyla-
tion would represent a new posttranslational modification in the
p53 field that adds to the long list of already known posttransla-
tional p53 modifications (Bode & Dong, 2004). So far it was
believed that the phosphorylation of p53 at Ser15 was one of the
initial steps of p53 activation (Bode & Dong, 2004; Meek & Ander-
son, 2009). Our data would however suggest that binding of
PHD1 to p53 and potential hydroxylation of p53 precede its phos-
phorylation adding specificity to the phosphorylation process of
p53 and directing p53 activity toward DNA repair and cytostatic
signaling.
Figure 7. PHD1 silencing impairs p53-mediated DNA repair by reducing p53 binding to the NER helicase XPB.
A Western blot for pH2AX and vinculin (vinc) in p53wt/wt and p53/ HCT116 cells after 24-h treatment with 300 lM 5-FU.
B Detection of pH2AX and vinc in p53S15A?p53/ HCT116 cells silenced for PHD1 and treated with 300 lM 5-FU for 24 h.
C Detection of pH2AX and vinc in HCT116 silenced with a second silencing construct of PHD1 and treated for 24 h with 300 lM 5-FU.
D Western blot for pH2AX and vinc in HCT116 treated for 20 h with 200 nM SN-38 or 24 h with 20 lM oxaliplatin.
E Western blot for pH2AX and vinc in p53R248/ HCT116 cells silenced for PHD1 upon treatment with 300 lM 5-FU for 24 h.
F Detection by Western blot of p53 and XPB from whole cell extracts (WCE) or after immunoprecipitation of p53 from cells silenced for Scr control or siPHD1 and
treated for 4 or 8 h with 300 lM 5-FU.
G Western blot for pH2AX and vinc in HCT116 silenced for PHD1 alone or in combination with silencing for XPB upon treatment with 300 lM 5-FU for 20 h.
H PHD1 hydroxylase activity allows the phosphorylation of p53 upon chemotherapy treatment in colorectal cancer cell lines. As a consequence, p53 can interact with
the NER machinery and more specifically with XPB. This promotes DNA repair and results in the resistance toward the cytostatic effects of chemotherapy (left panel).
On the other hand, when PHD1 is lacking, the p53-kinase p38a can no longer bind, and therefore, p53 phosphorylation upon chemotherapy treatment is prevented. In
absence of Ser15 phosphorylation, p53 is no longer able to bind XPB, thereby blocking the DNA repair-promoting capacity of p53. This leads to increased DNA damage
and thus enhanced apoptotic response to chemotherapy (right panel).
Data information: Vinc is used as a loading control in (A–E, G).
Source data are available online for this figure.
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When looking further downstream in the p53 pathway, our
results suggest that a reduction in p53 phosphorylation at Ser15
without altering the total p53 levels affects specifically the tran-
scription-independent DNA repair pathway of p53. Indeed, tran-
scription of some important p53 target genes such as CDKN1A,
MDM2, and PUMA is not altered upon PHD1 silencing after 5-FU
treatment. This is in line with some previous evidence showing
that p53 phosphorylation is not the main determinant of p53
transcriptional activity as p53 transcription can also be triggered by
mere p53 stabilization without phosphorylation (Stommel & Wahl,
2004; Kruse & Gu, 2009). This could explain the lack in transcrip-
tional differences observed in our model, but also uncovers a new
role for p53 phosphorylation at Ser15 in NER. Previous findings
have shown that p53 can positively influence NER and that p53
can do this independently of transcription through the binding with
XPB and XPD (Sengupta & Harris, 2005; Chang et al, 2008). In our
results, we did not observe binding between p53 and XPD, but
observed a robust binding between XPB and p53 after 5-FU treat-
ment, which was strongly reduced upon PHD1 silencing and thus
upon reduced p53 phosphorylation at Ser15, which is followed by
impaired DNA repair and resultant apoptosis. Despite that NER has
already been involved in resistance to chemotherapy (Dabholkar
et al, 2000; Reed et al, 2003; Bohanes et al, 2011), to our knowl-
edge, this is the first report showing that p53 phosphorylation can
affect the DNA repair machinery, though further investigations will
be required to explain how posttranslational modifications in p53
can elicit this effect.
Here, we also show that mutation of p53 in position R248, a hot
spot mutation in CRC, recapitulates the effects seen with wild-type
p53. So far, mutations in p53 have been considered to be inactivating
and rendering p53 incapable to perform any of its regular functions
(Muller & Vousden, 2013). However, our data clearly demonstrate
that a p53 DNA contact mutant is still regulated by PHD1 and retains
at least a partial DNA-repair-promoting activity. Therefore, potential
blockage of PHD1 could also be clinically relevant in patients
carrying DNA contact mutations in p53—which are frequently
reported in CRC.
The clinical usage of PHD1-specific inhibitors has been already
proposed in the context of breast cancer, ischemic liver disease, and
colitis (Zhang et al, 2009; Schneider et al, 2010; Tambuwala et al,
2010). Particularly in CRC, specificity of PHD inhibitors is warranted
because PHD2 inhibition has been shown to increase tumor growth
and PHD3 blockage has been associated with a reduced apoptotic
response to irradiation (Chan et al, 2009; Xie et al, 2012). With our
data, we pave the opportunity to design and validate PHD1-specific
inhibitors in colorectal cancer patients carrying wild-type or DNA
contact mutant p53 aiming to increase their sensitivity to currently
used chemotherapeutic treatments.
Materials and Methods
Cell culture
HEK293T human embryonic kidney cells, HCT116 human colon
carcinoma cells (containing wild-type p53: p53wt/wt HCT116, further
noted as HCT116; lacking p53: p53/ HCT116 and p53R248/
HCT116, a kind gift from Prof. Karen Vousden, Glasgow), and the
human colon cancer cell line LIM1215 (a kind gift from Prof. Sabine
Tejpar, Leuven) were maintained at 37°C at 95% air and 5% CO2 in
DMEM (Gibco, life technologies) supplemented with 10% fetal
bovine serum (FBS, Gibco), 2 mM L-glutamine (Gibco), and 1%
penicillin/streptomycin (PenStrep, Gibco). All cancer cell lines
underwent mycoplasma testing before their use. Negative
mycoplasma contamination status was verified using LookOut
Mycoplasma PCR Kit (Sigma) and MycoAlert Mycoplasma Detection
Kit plus Assay Control (Lonza). All cell lines were not maintained
longer than 10 passages in culture to perform experimental proce-
dures. Transfection of siRNA was performed with lipofectamine
RNAiMAX (Life Technologies) according to the supplier’s protocol.
Catalog numbers for the different siRNAs used can be found in
Table 1.
Cell treatments
The chemotherapeutics 5-fluorouracil (5-FU, Sigma-Aldrich), 7-ethyl-
10-hydroxycamptothecin (SN-38, Sigma-Aldrich), oxaliplatin (Selleck
Chemicals), MG-132 (Calbiochem) as well as the PHD inhibitor
dimethyloxaloylglycine (DMOG, Frontier Scientific) were prepared in
DMSO stock solutions and diluted to their final concentration in
DMEM (10% FBS, 2 mM L-glutamine, and 1% PenStrep). Treatment
times and doses were used as indicated in the results.
Western blot
Protein extraction was performed using RIPA buffer [50 mM Tris pH
8, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, and
0.1% sodium dodecyl sulfate (SDS)] containing phosphatase (Phos-
STOP Roche) and protease (Complete Roche) inhibitors. When the
detection of apoptosis was required, the supernatants of the cells
were also collected for Western blot analysis. The following anti-
bodies were used for the detection of the proteins by immunoblot-
ting: rabbit anti-PHD1 (Novus, NB100-310, 1/250 in 5% milk),
mouse anti-p53 (Santa Cruz Biotechnology, DO1, 1/4,000 in 5%
milk), rabbit anti-p53 (Santa Cruz Biotechnology, FL-393, 1/1,000 in
5% milk), mouse anti-vinculin (Sigma-Aldrich, V9131, 1/5,000 in
5% milk), rabbit anti-caspase-3 (Cell Signaling, #9665, 1/500 in 5%
BSA), rabbit anti-Flag (Sigma-Aldrich, F7425, 1/1,000 in 5% milk),
rabbit anti-phospho-serine 15 p53 (Cell Signaling, #9284, 1/1,000 in
5% BSA), rabbit anti-pH2AX (Cell Signaling, #2577, 1/1,000 in 5%
BSA), rabbit anti-cleaved parp (Cell Signaling, #5625, 1/1,000 in 5%
BSA), rabbit anti-p38 (Cell Signaling, #9212, 1/1,000 in 5% BSA),
and rabbit anti-XPB (Santa Cruz Biotechnology, sc-293, 1/500 in 5%
milk). Secondary goat anti-mouse and goat anti-rabbit antibodies
directly conjugated to horseradish peroxidase were used (Santa Cruz
Biotechnology, 1/4,000 in 5% milk), and blots were developed
using ECL (Life Technologies) or Super Signal West Femto (Thermo
Scientific) with a CCD camera (ImageQuantTM LAS 4000). All
Western blot experiments were repeated at least three times in inde-
pendent experiments, and uncropped figures can be found in the
Source Data.
Co-immunoprecipitation
Co-immunoprecipitation of PHD-Flagged proteins in HEK293T
cells was performed by lysing the cells in RIPA buffer. After
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pre-clearing of 1 mg of protein lysate with 30 ll of non-conjugated
Sepharose beads (GE Healthcare life sciences), 30 ll of ANTI-
Flag M2 Affinity Gel (Sigma-Aldrich, pre-blocked with 0.05%
BSA) was added to the pre-cleared lysates. After a 2-h incubation
at 4°C, the bead–sample complexes were washed three times with
RIPA buffer. Afterward, 20 lg of Flag peptide (Sigma-Aldrich)
diluted in 80 ll of TBS buffer [50 mM Tris–HCl pH 7.4, 150 mM
NaCl, containing protease inhibitors (Complete Roche)] was
added to the beads and incubated for 45 min at 4°C. Conse-
quently, the eluted proteins were analyzed by immunoblot as
described above.
Recombinant Flag-tagged PHD proteins were produced in Sf9
insect cells and were kindly provided by prof. Johanna Myllyharju
(University of Oulu). Two milliliters of the insect cell pellet were
homogenized in 200 ll of lysis buffer [150 mM NaCl, 100 mM
glycine, 0.1% Triton X-100, 10 lM DTT, 10 mM Tris pH 7.8,
5 lM FeSO4, containing protease inhibitors (Complete Roche)]
with 30 strokes in a glass Teflon homogenizer, while keeping on
ice. The homogenates were centrifuged for 15 min at 14,707 g.
The supernatant was filtered using a 0.45-lm filter and 20 ll
ANTI-Flag M2 Affinity Gel (Sigma-Aldrich) was added. After a
1-h incubation on a rotating wheel at 4°C, protein–bead
complexes were washed three times in TBS [50 mM Tris–HCl pH
7.4, 150 mM NaCl, 5 lM FeSO4, containing protease inhibitors
(Complete Roche)] and 1.24 lg recombinant p53 (a kind gift from
Prof. Alan Fersht, University of Cambridge) was added. After a
1-h incubation on a rotating wheel at 4°C, beads were washed for
three times with TBS buffer and 20 lg of Flag peptide (Sigma-
Aldrich) diluted in 80 ll of TBS buffer was added to elute protein
complexes from the beads by rotating for 1 h at 4°C. A small frac-
tion of the eluate was then loaded on homemade polyacrylamide
gels for Western blot detection.
Endogenous immunoprecipitation of the p53–PHD1 interaction
was performed in HCT116 cells silenced for PHD1 or p53 or a
scrambled control. Immunoprecipitation was performed with
protein G dynabeads (Life Technologies) crosslinked to mouse
anti-p53 (86 ng Santa Cruz DOI, 86 ng Santa Cruz BPp53-12, and
13 ng Merck Millipore OP03/ll beads) or mouse IgG control
(185 ng Santa Cruz/ll beads) antibodies with BS3 (Life Technolo-
gies) according to the manufacturers’ protocol. Cells were then
lysed in Saito’s modified lysis buffer [50 mM Tris–HCl pH 7.4,
0.15 M NaCl, 0.5% Triton X-100, 5 mM EDTA containing phos-
phatase (PhosSTOP Roche) and protease (Complete Roche)] and
2.5 mg of protein was added to 15 ll of mouse anti-p53- or
mouse IgG-crosslinked dynabeads. The lysates were incubated for
2 h rotating at 4°C, after which they were washed 3 times with
Saito’s modified lysis buffer, eluted by boiling 10 min in 40 ll
1× LDS buffer (Life Technologies). Supernatants were collected,
DTT was added to a final concentration of 20 mM, and the
samples were further boiled for 10 min after which they were
analyzed by immunoblot as described above with the following
antibodies: 1/3,000 mouse anti-p53 (DOI Santa Cruz) in 5% milk
Table 1. Sequences or ordering information of the silencing constructs used.
si/shRNA Reference
scramble IDT: NC-1
siPHD1 IDT: HSC.RNAI.N053046.12.2
HSC.RNAI.N053046.12.1
siPHD2 Ambion (Life Technologies): s99984
siPHD3 Ambion (Life Technologies): s41320
siATM IDT: HSC.RNAI.N000051.12.1
siATR IDT: HSC.RNAI.N001184.12.1
siChk1 IDT: HSC.RNAI.N001114.12.1
siChk2 IDT: HSC.RNAI.N00719412.2
sip38a Ambion (Life Technologies):
Hss 102353
Hss 102352
siDNA-PK IDT: HSC.RNAI.N001081640.12.1
siHIF-1a IDT: HSC.RNAI.N001530.12.3
siHIF-2a IDT: HSC.RNAI.N001430.12.3
siXPB IDT: HSC.RNAI.N000122.12.1
mirSIMA A kind gift from Prof. Acker (University of Giessen)
Top sequence: TGCTGCATGAATATCTCTGTCTCCTTGTTTTGGCCACTGACTGACAAGGAGACAG ATATTCATG
Bottom sequence: CCTGCATGAATATCTGTCTCCTTGTCAGTCAGTGGCCAAAACAAGGAGACAGAGA TATTCATGC
mirPHD1 A kind gift from Prof. Acker (University of Giessen)
Top sequence: TGCTGGATGCTAGCTGATACTTGTCTGTTTTGGCCACTGACTGACAGACAAGTCAGCTAGCATC
Bottom sequence: CCTGGATGCTAGCTGACTTGTCTGTCAGTCAGTGGCCAAAACAGACAAGTATCAGCTAGCATCC
pTripz-shScr RHS4750 (GE Healthcare)
pTripz-shPHD1 V3THS_377151 (GE Healthcare)
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and 1/200 sheep anti-PHD1 (200 lg/ml R&D Systems AF6394) in
5% BSA.
Quantitative real-time PCR (qRT–PCR)
RNA from cells was extracted using the Qiagen Mini kit following the
manufacturer’s protocol. One microgram of RNA was reverse-tran-
scribed to cDNA by using the Qiagen QuantiTect Reverse
Transcription kit, according to the manufacturer’s protocol. After-
wards, the cDNA was diluted 10 times before further use. qRT–PCR
was performed using commercially available primers for the studied
genes (Table 2) and TaqMan Fast Universal PCR Master Mix
(Applied Biosystems). In a total volume of 10, 2 ll of the diluted
cDNA was added to 500 nM primers and Fast Master Mix and was
pipetted in a 96-well MicroAmp plate (Applied Biosystems). This
plate was analyzed on the 7500 Fast Real-time PCR system (Applied
Biosystems). Gene transcription was presented as the number of
mRNA copies of the gene of interest with respect to the b-actin copies
in each sample.
Immunocytochemistry
HCT116 cells seeded on coverslips in 12-well format were stained
according to the manual of the ApopTag Fluorescein In Situ Apop-
tosis Detection Kit (Merck Millipore), and the apoptotic area was
quantified by microscopic analysis with an Olympus BX41 micro-
scope and CellSense imaging software. ApopTag analysis showing
the average  s.e.m. from three biological replicates wherefrom
each time three fields were analyzed.
Cell cycle analysis
Supernatants derived from HCT116 cells were collected, and adher-
ent cells were subsequently trypsinized, added to the supernatant
previously collected, and centrifuged at 300 g for 5 min. After one
wash with PBS, cells were fixed with 1 ml of 70% ethanol. Cells
were incubated 2 h or overnight at 4°C, prior to another centrifuga-
tion at 300 g for 5 min. Supernatant was removed and the pellet
was resuspended in 200 ll of PBS, containing 500 lg of RNase
(10 mg/ml). About 200 ll of propidium iodide (0.1 mg/ml) was
added to a final volume of 400 ll. Samples were incubated for
1–2 h at 37°C and subsequently analyzed by fluorescence-activated
cell sorting by using FACS Canto II (BD Bioscience). FACS analysis
was performed on three independent experiments wherefrom a
representative experiment is shown.
ELISA nucleosome detection
The nucleosome detection was performed by using the Roche Cell
Death Detection ELISAPLUS according to the manufacturer’s
protocol. ELISA was performed in two independent experiments
with three biological replicates each, wherefrom one representative
experiment is shown.
Stable cell line generation
Full-length Flag-tagged wild-type and different proline mutant forms
of p53 were generated by Genscript in a lentiviral vector where p53
is under the RSV promoter as described before (Kaeser et al, 2004).
A small amount of lentivirus was used to transduce the p53/
HCT116 cells in order to obtain one copy of the lentiviral vector/
cell. Selection with puromycin (Sigma-Aldrich) was then performed
to achieve a homogeneous population.
In vitro kinase assay
The Flag-tagged p53 proteins were immunoprecipitated from whole
cell extracts dissolved in lysis buffer [50 mM Tris–HCl, pH 7.5,
150 mM NaCl, 1% Triton X-100, 2 mM EDTA, 2 mM EGTA, 10 mM
Na4P2O7, 1 mM PMSF, and complete protease inhibitor cocktail
tablet (Roche)]. To recover Flag p53 immunoprecipitates, 500 lg of
total protein was incubated with 2 lg Flag antibody for 1 h at 4°C
before Sepharose beads (30 ll per reaction mixture) were added for
12 h. After washing with lysis buffer, the immunocomplexes were
washed twice with kinase assay buffer (25 mM MOPS pH 7.2,
25 mM MgCl2, 5 mM EGTA, 2 mM EDTA, 250 lM DTT, 6 mM
b-glycerophosphate). Then, the samples were incubated in 10 ll
kinase assay buffer containing 20 ng of active, recombinant full-
length p38 (SignalChem), and 250 lM ATP at 30°C for 25 min.
Thereafter, proteins were denaturated by incubating with 4× SDS
sample buffer at 95°C for 10 min. Following separation of the
proteins by 10% SDS–PAGE, the gel was blotted onto a nitrocellu-
lose membrane, and proteins were analyzed as described before.
Experiment was performed twice with the image depicted being a
representative of both independent experiments.
Colony formation assay
p53wt/wt and p53/ HCT116 transduced with a doxycycline-indu-
cible shScr or shPHD1 construct were treated for 24 h with 1 lg/ml
doxycycline (Sigma-Aldrich). Following treatment for 8 h with
300 lM 5-FU or control, the cells were detached and seeded at a cell
density of 2,000 cells/6 wells in culture medium containing 1 lg/ml
doxycycline. Afterward, colony formation capacity was followed
over time and medium was changed every 2–3 days to maintain
doxycycline treatment. Colonies were stained with crystal violet and
analyzed with ImageJ. Experiments are performed three times, and
analysis is a representative experiment.
Table 2. Primers used for qRT–PCR.
Primers Reference
PHD1 Applied Biosystems: Hs01091275
PHD2 Applied Biosystems: Hs00254392
PHD3 Applied Biosystems: Hs00222966
b-actin IDT: Hs PT39a22214847
ATM IDT: Hs PT56a2596352
ATR IDT: Hs PT56a27318728
Chk1 IDT: Hs PT583518318
Chk2 IDT: Hs PT56a24327520
p38a IDT: Hs PT5840355791
DNA-PK IDT: Hs PT56a25320213
XPB IDT: Hs PT5815606497
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Tumor experiments
NMRI nude (Harlan) mice, 6–8-week-old males with a weight
between 30 and 40 g, were maintained under SPF conditions with
free access to water and food pellets in cages with 4–6 mice/cage.
Mice were injected subcutaneously in the flank with 3 × 106 cells of
the stably transduced p53wt/wt HCT116 p53/ HCT116 shScr or
shPHD1 cell lines. Tumors were measured in a blinded manner with
a caliper, and tumor volume was calculated using the formula:
V = p × [d2 × D]/6, where d is the minor tumor axis and D is the
major tumor axis. When tumors reached a volume of 200 mm3, mice
were given access to drinking water containing 1 mg/ml doxycycline
in H2O containing 5% sucrose until the end of the experiment. Two
days later, when tumors reached approximately 250 mm3, the mice
were randomly assigned to receive either treatment with 100 mg/kg
(i.p.) or a control solution was started. Afterwards, mice were
treated twice more at days 7 and 14 after treatment start. Eighteen
hours after the last dose of 5-FU, mice were euthanized. Housing and
all experimental animal procedures were approved by the Institu-
tional Animal Care and Research Advisory Committee of the KU
Leuven (P096-2012) and reported according to the ARRIVE guide-
lines. The experiments were performed two times, with the experi-
ment shown being a representative experiment.
Statistics
Data entry and all analyses were performed in a blinded fashion. All
statistical analyses were performed using GraphPad Prism software.
Statistical significance was calculated by two-tailed unpaired t-test
on two experimental conditions or two-way ANOVA when repeated
measures were compared, with P < 0.05 considered statistically
significant. Exact P-values are indicated in the figure legends, except
when P < 0.0001 as prism does not provide an exact P-value below
this point. Data were tested for normality using the D’Agostino–
Pearson omnibus test (for n > 8) or the Kolmogorov–Smirnov test
(for n ≤ 8) and variation within each experimental group was
assessed. Detection of mathematical outliers was performed using
the Grubbs’ test in GraphPad. Sample sizes for all experiments were
chosen based on previous experiences, and n-numbers given in the
figure legends always represent biological replicates. All graphs
show mean values  s.e.m.
Expanded View for this article is available online:
http://embomolmed.embopress.org
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